SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1481)3/6/2004 4:34:21 AM
From: Icebrg  Read Replies (2) of 1826
 
Dr. Cancerblogger notes the following:

oncologynews.info

Oncologists have commonly given the steroid, dexamethasone (Decadron), with 5-HT3 antagonists for control of chemotherapy-induced nausea. This harkens back to the old days, when the drugs available to control nausea were limited. It was discovered that dexamethasone was effective in decreasing delayed-onset nausea, and since then it was a standard part of anti-emetic therapy. Now, data from the University of Chicago suggests that dexamethasone may inhibit the efficacy of drugs such as adriamycin and paclitaxel against breast cancer. Apparently, dexamethasone upregulates levels of the genes, SGK-1 and MKP-1, which inhibit cell death. Indeed increased expression of this gene is already observed in breast, ovarian and pancreatic cancer cells. Although the authors caution that they are not advocating against the use of dexamethasone, certainly the newer anti-emetic agents, such as aprepitant, may obviate the need for routine use of dexamethasone.

eurekalert.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News